Schroder Investment Management Group Purchases 405 Shares of Agilent Technologies, Inc. (NYSE:A)

by · The Markets Daily

Schroder Investment Management Group increased its position in shares of Agilent Technologies, Inc. (NYSE:A – Free Report) by 0.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 88,300 shares of the medical research company’s stock after buying an additional 405 shares during the period. Schroder Investment Management Group’s holdings in Agilent Technologies were worth $11,847,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Flynn Zito Capital Management LLC lifted its holdings in Agilent Technologies by 3.8% during the fourth quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company’s stock worth $251,000 after buying an additional 69 shares during the period. IFP Advisors Inc lifted its position in shares of Agilent Technologies by 17.7% during the fourth quarter. IFP Advisors Inc now owns 458 shares of the medical research company’s stock valued at $62,000 after buying an additional 69 shares during the last quarter. Tiemann Investment Advisors LLC boosted its holdings in shares of Agilent Technologies by 5.6% in the 4th quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company’s stock valued at $191,000 after buying an additional 75 shares in the last quarter. Rothschild Investment LLC grew its position in shares of Agilent Technologies by 19.2% in the 4th quarter. Rothschild Investment LLC now owns 491 shares of the medical research company’s stock worth $66,000 after buying an additional 79 shares during the last quarter. Finally, Ascent Group LLC raised its stake in shares of Agilent Technologies by 4.1% during the 3rd quarter. Ascent Group LLC now owns 2,209 shares of the medical research company’s stock worth $328,000 after acquiring an additional 87 shares in the last quarter.

Agilent Technologies Stock Performance

Shares of NYSE A opened at $109.63 on Friday. The company has a 50 day simple moving average of $131.31 and a two-hundred day simple moving average of $136.00. The stock has a market cap of $31.25 billion, a price-to-earnings ratio of 25.20, a PEG ratio of 3.20 and a beta of 1.19. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56. Agilent Technologies, Inc. has a 12 month low of $109.57 and a 12 month high of $155.35.

Agilent Technologies (NYSE:A – Get Free Report) last posted its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The company had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. As a group, analysts predict that Agilent Technologies, Inc. will post 5.57 earnings per share for the current year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be paid a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.90%. Agilent Technologies’s payout ratio is 22.76%.

Insider Buying and Selling

In related news, Director Daniel K. Podolsky sold 1,819 shares of the stock in a transaction on Monday, March 31st. The shares were sold at an average price of $116.46, for a total transaction of $211,840.74. Following the sale, the director now directly owns 35,737 shares of the company’s stock, valued at approximately $4,161,931.02. This represents a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Rodney Gonsalves sold 1,908 shares of Agilent Technologies stock in a transaction on Monday, March 17th. The shares were sold at an average price of $121.98, for a total transaction of $232,737.84. Following the completion of the transaction, the vice president now directly owns 21,786 shares of the company’s stock, valued at $2,657,456.28. The trade was a 8.05 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,638 shares of company stock valued at $731,229 over the last ninety days.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on A shares. Bank of America cut their price target on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. StockNews.com upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 24th. Wells Fargo & Company reduced their target price on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a research report on Monday, December 9th. Barclays upgraded Agilent Technologies from an “underweight” rating to an “equal weight” rating and boosted their price target for the stock from $135.00 to $145.00 in a research note on Monday, February 10th. Finally, Citigroup increased their price objective on shares of Agilent Technologies to $165.00 and gave the company a “buy” rating in a research report on Thursday, December 19th. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Agilent Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $150.83.

Read Our Latest Report on Agilent Technologies

Agilent Technologies Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Recommended Stories